Thursday, April 3, 2025
4/3/2025
University of Rochester Wilmot Cancer Institute Support Grant - The mission of the Wilmot Cancer Institute (Wilmot) at the University of Rochester (UR) is to provide the highest quality treatment and care, through expert and innovative medicine, science, and education, for any patient burdened by any cancer within Central and Western New York, and beyond. Wilmot serves a distinct population in a catchment area of more than three million people confronted with a cancer incidence significantly above national averages, due to a disproportionately aging population, tobacco use, and predominantly poor urban and rural communities. During a 50-year history, Wilmot’s research has led to changes in oncology standards of care and paradigm-shifting discoveries, including the science behind the HPV vaccine. Wilmot investigators are respected internationally as leaders in cancer control and supportive care research, and Wilmot’s extraordinary expertise in this area has been recognized through a longstanding National Cancer Institute (NCI)-funded National Community Oncology Research Program research base award. Wilmot also benefits from outstanding visibility and strength in hematological malignancy clinical and translational research. Wilmot has created three transdisciplinary research programs (Genetics, Epigenetics and Metabolism; Cancer Microenvironment; and Cancer Prevention and Control), with a unifying research theme of “aging and cancer”. Wilmot members continue to push the frontiers of cancer science: identifying bone marrow microenvironment characteristics that support myelodysplastic syndrome; defining the role of geriatric assessment in medical oncology; harnessing the innate immune system to attack pancreatic cancer; and discovering mediators of cancer resistance and novel cancer cell vulnerabilities with promise for therapeutic translation. Attention to Wilmot’s 27-county catchment area through prevention services and research is achieved with bidirectional collaboration via a robust Community Cancer Action Council and associated Research Advisory Committees. Major institutional investments include space, senior scientists, junior faculty recruitment, and a clinical trial infrastructure resulting in Wilmot being a designated Lead Academic Participating Site of the National Clinical Trials Network. With support of the UR, the community, and a P30 Cancer Center Support Grant, and under the leadership of Director Jonathan W. Friedberg, MD, MMSc (CM), Wilmot will: 1) improve patient outcomes through paradigm-shifting, transdisciplinary discovery, integrating basic, translational, and population science; 2) translate basic and population science discoveries to benefit patients through interventional clinical trials; 3) enhance mentoring and career development in cancer science for researchers at all career stages, through interdisciplinary curricula and fostering an inclusive workforce culture; and 4) engage communities in the Central and Western New York catchment area to uncover unmet needs and implement responsive cancer prevention, community-driven research, dissemination efforts, and education programs. Wilmot conducts all of these activities with emphasis on diversity, equity, and inclusion, and guided by a Strategic Plan.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).